rasagiline mesylate · Teva · NDA 021641
Azilect
Earliest generic entry, as listed · earliest of 2 marketed strengths
27 Aug 2027
Blocked by patent: US 7815942.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7815942 | substance, product, use U-219 | 27 Aug 2027 |
| US 7572834 | product | 5 Dec 2026 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 24 Oct 2026Enters 12-month window basis: patent · 021641-00227 Aug 2027
- 24 Oct 2026Enters 12-month window basis: patent · 021641-00127 Aug 2027
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021641 · 001 · RLD | tablet, oral | EQ 0.5MG BASE | 27 Aug 2027 |
| 021641 · 002 · RLD | tablet, oral | EQ 1MG BASE | 27 Aug 2027 |